Real Time-PCR (qPCR) is the fastest growing sector, North America is the largest market
Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Market Drivers
The market for RNA analysis is primarily driven by the growing number of RNA-based therapeutics and mRNA vaccines in development, shifting the analytical focus from genomic DNA to dynamic transcriptomics. As biopharmaceutical research expands into areas like oncology and rare genetic disorders, the need for stringent analytical quality control, covering aspects such as sequence identity and capping efficiency, has become critical. This heightened R&D activity fuels demand for high-precision assays capable of validating emerging modalities like circular RNA and siRNA, with over 3,200 global clinical trials reported in Q3 2025 by the American Society of Gene & Cell Therapy.Additionally, advancements in next-generation sequencing and high-throughput analysis are propelling market expansion by overcoming previous limitations in cost and throughput. Innovations in sequencing chemistry and platform design now enable laboratories to achieve deeper transcriptomic insights more rapidly and affordably, as exemplified by Pacific Biosciences' SPRQ-Nx chemistry, which is projected to reduce sequencing costs by up to 40%. This enhanced accessibility is evident in the broader adoption of specialized tools, such as the 19% increase in spatial consumables revenue for 10x Genomics in Q3 2025, indicating a rising dependence on advanced platforms for intricate tissue analysis.
Market Challenges
A significant obstacle to the Global RNA Analysis Market's growth is the bioinformatic complexity involved in processing extensive transcriptomic data. Modern high-throughput sequencing platforms produce increasingly vast datasets, often overwhelming standard laboratory infrastructure's storage and computational capabilities. This technological disparity creates a critical bottleneck where the sheer volume of raw data exceeds researchers' capacity to extract meaningful biological insights, leading to operational delays in drug discovery and clinical validation.This analytical hurdle disproportionately affects smaller research institutions and emerging biotechnology companies lacking the financial resources for high-performance computing or dedicated data science expertise. Their inability to process complex datasets efficiently restricts the broader adoption of advanced RNA analysis tools, thus limiting the market's overall reach. The challenge is intensified by the considerable clinical activity globally, with over 3,200 trials underway as of November 2025, according to the American Society of Gene & Cell Therapy, each contributing to the immense data load that strains current analytical capacities.
Market Trends
The Global RNA Analysis Market is being transformed by the integration of artificial intelligence (AI) and machine learning (ML) into bioinformatics, which addresses previous data analysis bottlenecks hindering clinical adoption. Research laboratories are increasingly utilizing AI-driven predictive models to link intricate transcriptomic datasets with clinical outcomes, thus accelerating the development of precision oncology and personalized therapies.This shift from manual data curation to algorithmic interpretation is reflected in the significant financial growth of companies focused on AI-enhanced genomic profiling, such as Tempus AI's Genomics division, which saw a 24.4% year-over-year revenue increase to $451.7 million in fiscal year 2024. This growth highlights the industry's increasing dependence on computational platforms to convert raw sequencing data into valuable biological insights. Concurrently, the market is experiencing a notable convergence of transcriptomics with proteomics, spurred by spatial biology technologies that map gene expression within the architectural context of tissues.
This multi-omics strategy enables researchers to combine RNA sequencing data with protein markers, uncovering cellular interactions and microenvironmental details that single-cell dissociation methods cannot capture. The commercial strength of this segment is growing as pharmaceutical companies incorporate spatial profiling tools into their drug safety and efficacy studies, with Bio-Techne's Diagnostics and Spatial Biology segment revenue rising 6% to $346.3 million for fiscal year 2025, indicating ongoing demand for platforms that maintain spatial context. This trend signifies the sector's progression from basic sequence identification to sophisticated, spatially resolved tissue characterization.
Key Market Players
- Agilent Technologies, Inc.
- F. Hoffmann-La Roche Ltd
- Illumina, Inc.
- QIAGEN NV
- Thermo Fisher Scientific, Inc.
- Eurofins Scientific
- Merck KgaA
- Bio-Rad Laboratories, Inc.
- Pacific Bioscience of California, Inc.
- Affymetrix, Inc.
Report Scope
In this report, the Global RNA Analysis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:RNA Analysis Market, by Product:
- Kits & Reagents
- Services
- Instruments
RNA Analysis Market, by Technology:
- Real Time-PCR (qPCR)
- Microarray
- Sequencing
- others
RNA Analysis Market, by Application:
- Epigenetics
- Infectious Diseases & Pathogenesis
- Alternative RNA Splicing
- RNA Structure & Molecular Dynamics
- Development & Delivery of RNA Therapeutics
RNA Analysis Market, by End-use:
- Government Institutes & Academic Centers
- Pharmaceutical & Biotechnology Companies
- Hospitals & Clinics
- others
RNA Analysis Market, by Region:
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global RNA Analysis Market.Available Customizations:
With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:Company Information
- Detailed analysis and profiling of additional market players (up to five).
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- Agilent Technologies, Inc.
- F. Hoffmann-La Roche Ltd
- Illumina, Inc.
- QIAGEN NV
- Thermo Fisher Scientific, Inc.
- Eurofins Scientific
- Merck KGaA
- Bio-Rad Laboratories, Inc.
- Pacific Bioscience of California, Inc.
- Affymetrix, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 185 |
| Published | May 2026 |
| Forecast Period | 2025 - 2031 |
| Estimated Market Value ( USD | $ 10.12 Billion |
| Forecasted Market Value ( USD | $ 17.77 Billion |
| Compound Annual Growth Rate | 9.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |


